• ureteral stents market was valued at approximately s projected to grow at a compound annual growth from 2025 to 2030, reaching an estimated by 2030.

• North America led the market in 2024 with a 37% share, driven by high prevalence of urological disorders and advanced healthcare infrastructure.

• The polymer stents segment accounted for 68% of the market in 2024, favored for their flexibility and reduced complication rates.

• Kidney stones represented the largest application segment in 2024, comprising 38% of the market share.

• Urinary incontinence is anticipated to exhibit the fastest growth rate during the forecast period, driven by an aging population and increased awareness of treatment options.

• Technological advancements, such as the development of biodegradable stents, are addressing concerns related to secondary removal procedures and enhancing patient comfort.

• Key market players include Boston Scientific, Cook Medical, B. Braun, Coloplast, and Teleflex, focusing on innovation and strategic partnerships to strengthen their market presence.

• In June 2024, Boston Scientific launched a new soft ureteral stent aimed at reducing patient discomfort and improving urinary drainage, reinforcing its leadership in advanced urology solutions.

• In March 2023, Coloplast acquired Vertiflex’s urology product division, expanding its portfolio of ureteral access devices and strengthening its position in the urological care market.

In this report, the Ureteral Stents Market has been segmented by Product Type, Material, Application, End-User and Geography. These segmentation axes highlight demand patterns shaped by rising kidney stone prevalence, growing urological procedure volumes, advancements in stent materials, and increasing minimally invasive surgery adoption across global healthcare systems.

Ureteral Stents Market, Segmentation by Product Type

The Product Type segmentation reflects differences in functional design, patient comfort, and procedural compatibility. Demand grows as urology departments adopt stents engineered for reduced encrustation, improved drainage, and lower complication rates. Increasing adoption of minimally invasive procedures has driven annual stent usage up by more than 40% across major healthcare centers.

Open End Stents

Open End Stents support efficient drainage and guidewire passage, making them widely used in diagnostic and therapeutic urological procedures. Their versatility contributes to adoption growth above 30%, particularly for stone-related obstructions.

Closed End Stents

Closed End Stents offer enhanced patient comfort and reduce irritation at the renal end. Their design supports secure placement and is preferred in long-term implantation scenarios, achieving usage increases above 25%.

Double Pigtail Stents

Double Pigtail Stents dominate market share due to their superior anchoring ability, reduced migration risk, and broad procedural suitability. Clinical adoption surpasses 50% in many settings due to proven performance in both short- and long-term interventions.

Multiloop Stents

Multiloop Stents provide enhanced fixation and drainage optimization, especially for complex urological conditions. Their growing clinical acceptance results from their ability to lower migration rates by more than 35%.

Ureteral Stents Market, Segmentation by Material

The Material axis evaluates stents based on durability, biocompatibility, encrustation resistance, and patient tolerance. Material innovation remains a major market driver, supporting a 45% increase in advanced polymer usage and rising interest in metallic stents for difficult obstructions.

Metallic Stents

Metallic Stents deliver high strength and long-term patency, making them ideal for patients with chronic obstructions or recurrent strictures. Their durability can reduce replacement frequency by more than 40%, supporting their use in complex cases.

Polymer Stents

Polymer Stents represent the most widely used material category, driven by flexibility, biocompatibility, and patient comfort. Anti-encrustation coatings improve clinical performance by 30–50%, supporting broad adoption across routine urological procedures.

Ureteral Stents Market, Segmentation by Application

The Application segmentation reflects adoption across diverse urological conditions including acute obstructions, chronic diseases, and surgical support scenarios. Rising prevalence of kidney stones and urological cancers contributes to application expansion exceeding 50% worldwide.

Kidney Stones

Kidney Stones represent the largest application area, supported by rising incidence and increased use of stents during lithotripsy, ureteroscopy, and post-operative recovery. Usage growth exceeds 45% as stone-related procedures rise globally.

Kidney Transplantation

Kidney Transplantation applications rely on stents to maintain ureteral integrity, prevent leaks, and support healing. Adoption increases by over 35% with rising transplant volumes and improved graft survival rates.

Tumors

Tumors within the urinary tract frequently require stents to relieve obstruction and support patient comfort. Oncology-driven usage grows by more than 30%, especially in cases of advanced or recurrent malignancies.

Urinary Incontinence

Urinary Incontinence applications involve stents designed to maintain flow and relieve pressure in obstructive or dysfunctional urinary pathways. Increased urological disorder prevalence has accelerated adoption by over 25%.

Others

The Others category includes trauma-related obstruction, congenital abnormalities, and postoperative stabilization needs. Adoption remains steady due to broad procedural applicability across diverse clinical conditions.

Ureteral Stents Market, Segmentation by End-User

The End-User segmentation reveals utilization patterns across institutional healthcare facilities. Growth in minimally invasive surgery volumes, strengthened urology infrastructure, and rising demand for postoperative care contribute to overall end-user adoption above 40%.

Hospitals

Hospitals account for the largest share due to high surgical volumes, access to advanced imaging, and availability of multidisciplinary expertise. Adoption typically exceeds 55%, driven by complex urological case management.

Clinics

Clinics demonstrate rising adoption as outpatient urology services expand. Their usage increases by more than 30% due to streamlined workflows and rising patient preference for minimally invasive procedures.

Ambulatory Surgical Centers (ASCs)

Ambulatory Surgical Centers (ASCs) show strong growth as day-surgery adoption accelerates. ASCs support fast turnaround and cost efficiencies, enabling usage increases above 35% in many developed markets.

Ureteral Stents Market, Segmentation by Geography

The Geography segmentation highlights regional variation in disease prevalence, healthcare expenditure, surgical infrastructure, and adoption of advanced stent technologies. Developed regions demonstrate high procedural volumes, while emerging regions grow at rates above 45% due to expanding healthcare access.

North America

North America leads the market due to high urological surgery volumes, widespread use of minimally invasive procedures, and rapid adoption of polymer-coated stents. Regional growth exceeds 50% driven by rising kidney stone prevalence.

Europe

Europe demonstrates strong demand supported by well-developed healthcare systems and high awareness of urological disease management. Adoption of advanced stents grows past 45% with significant usage in Western Europe.

Asia Pacific

Asia Pacific exhibits the fastest growth, driven by increasing patient population, higher rates of kidney disorders, and rapid expansion of urology care infrastructure. Market expansion surpasses 55% in several key countries.

Middle East & Africa

Middle East & Africa shows steady progress, driven by growing access to surgical care and rising burden of urinary tract obstructions. Adoption increases by over 30% in major urban centers.

Latin America

Latin America experiences moderate but consistent adoption supported by improving healthcare access, rising kidney stone incidence, and broader use of minimally invasive procedures, contributing to regional growth above 35%.

This report provides an in depth analysis of various factors that impact the dynamics of Ureteral Stents Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Rising prevalence of kidney stones and urological disorders
• Growing geriatric population with higher risk of urinary complications
• Increasing adoption of minimally invasive urological procedures

• Technological advancements in stent materials and designs - Technological advancements in stent materials and designs are significantly driving growth in the ureteral stents market. Innovations such as biodegradable stents, anti-microbial coatings, and more flexible, patient-friendly materials have improved stent performance, reduced complications, and enhanced patient comfort. These developments address long-standing issues like infection, encrustation, and discomfort, making next-generation ureteral stents more effective and reliable for both short-term and long-term applications.
  
  Enhanced designs that offer better drainage, easier insertion, and compatibility with minimally invasive procedures are also gaining popularity among urologists. As healthcare providers increasingly seek advanced and patient-centric urological solutions, the demand for technologically superior stents continues to rise. This trend not only improves clinical outcomes but also supports the broader adoption of ureteral stents in managing various urinary tract disorders.

Restraints

• Complications associated with stents
• Stringent regulatory requirements
• High cost of procedures

• Limited reimbursement policies - Limited reimbursement policies act as a significant restraint on the growth of the ureteral stents market. In many regions, healthcare systems offer only partial or no coverage for stent placement procedures, making treatment costly for both providers and patients. This financial burden can lead to delays in necessary interventions or a preference for less effective alternatives, ultimately impacting patient outcomes and stent adoption rates.

  The lack of comprehensive reimbursement particularly affects the use of advanced or premium stent technologies, which tend to be more expensive. Hospitals and clinics may hesitate to adopt these innovations due to uncertain returns on investment. Without adequate policy support, the full potential of technological advancements in ureteral stents remains underutilized, limiting market growth in both developed and developing healthcare settings.

Opportunities

• Innovative product developments
• Minimally invasive techniques

• Strategic collaborations and partnerships: The ureteral stents market has witnessed significant growth in recent years, driven by strategic collaborations and partnerships among key players in the industry. These collaborations aim to leverage each company's strengths and resources to enhance product development, expand market reach, and improve patient outcomes. Through partnerships, companies can combine their expertise in medical device technology, research and development, and marketing to bring innovative solutions to the market more efficiently.

  One prominent trend in the ureteral stents market is collaborations between medical device manufacturers and healthcare providers. By working closely with urologists, hospitals, and clinics, manufacturers gain valuable insights into the evolving needs of patients and clinicians. This collaboration often leads to the development of stents that are more tailored to specific clinical scenarios, improving patient comfort and reducing complications. Additionally, partnerships with healthcare providers can facilitate clinical trials and real-world evidence generation, supporting regulatory approvals and reimbursement decisions.

Ureteral Stents Market is witnessing strong competition as medical device manufacturers focus on advanced, biocompatible, and durable stents for urological applications. Nearly 62% of leading players adopt integrated strategies involving partnerships and collaboration with hospitals, clinics, and distributors, while 38% emphasize R&D-driven innovation. This approach ensures steady growth across endourology, urology surgeries, and patient care segments.

Market Structure and Concentration
The market demonstrates a semi-consolidated structure, with approximately 55% of share held by global medical device manufacturers and 45% by regional or specialized firms. Larger companies pursue merger activities and international expansion, while smaller players differentiate through material and design-level innovation. This balance sustains competitive intensity and supports continuous growth in ureteral stent solutions.

Brand and Channel Strategies
Around 65% of sales are generated through direct hospital contracts and surgical centers, while 35% flow via distributors, specialty suppliers, and e-commerce medical platforms. Companies enhance strategies by strengthening brand recognition and fostering collaboration with healthcare providers. This approach drives regional expansion and ensures sustainable growth in stent adoption.

Innovation Drivers and Technological Advancements
Close to 70% of manufacturers invest in bioresorbable stents, anti-encrustation coatings, and patient-friendly designs. These technological advancements improve safety, durability, and clinical outcomes. R&D-led innovation combined with strategic partnerships accelerates product development, strengthens competitiveness, and drives measurable growth in the ureteral stents market.

Regional Momentum and Expansion
North America and Europe together account for nearly 57% of the market share, supported by advanced healthcare infrastructure and high surgical adoption. Asia-Pacific represents around 40%, driven by industrial expansion and increasing urological procedures. Companies adopt regional strategies and collaboration with local hospitals to enhance accessibility, ensuring sustained growth.

Future Outlook
The market is projected to grow over 6% annually, fueled by rising urological disorders and demand for advanced stent technologies. Companies will focus on merger initiatives, strategic partnerships, and continuous innovation. With ongoing technological advancements and regional expansion, the ureteral stents sector demonstrates a promising future outlook.

Key players in Ureteral Stents Market include:

• Boston Scientific Corporation
• Cook Medical
• Becton, Dickinson and Company (BD)
• B. Braun Melsungen AG
• Teleflex Incorporated
• Coloplast Ltd.
• Olympus Corporation
• Medline Industries, LP
• Merit Medical Systems, Inc.
• Allium Medical
• Pnn Medical A/S
• UROMED Kurt Drews KG
• Taewoong Medical
• Richard Wolf GmbH
• KARL STORZ

In this report, the profile of each market player provides following information:

• Market Share Analysis
• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis